New Drug Information

- **Dyanavel™ XR (amphetamine extended-release oral suspension)**: The Food and Drug Administration (FDA) approved Tris Pharmaceuticals’ Dyanavel XR, an extended release suspension for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6 and older.

- **Veltassa™ (patiromer)**: The FDA approved Relypsa’s potassium-binding polymer, Veltassa, for the treatment of hyperkalemia. The drug is anticipated to launch in January 2016. It is to be used in treating patients with chronic kidney disease (CKD).

- **Vivlodex™ (meloxicam)**: Iroko Pharmaceuticals received FDA approval for Vivlodex for management of osteoarthritis pain. Vivlodex is a low-dose, once-daily meloxicam formulated in SoluMatrix® technology, similar to Iroko’s Zorvolex™ and Tivorbex™.

- **MorphaBond™ ER (morphine, extended release)**: The FDA approved Inspirion Delivery Technologies’ MorphaBond ER. This is an abuse-deterrent, extended-release formulation of morphine. It is for treatment of pain severe enough to require long-term daily, around-the-clock opioid treatment, where alternative options are inadequate.

- **Enstilar® (calcipotriene and betamethasone, aerosol foam)**: Leo Pharmaceuticals’ received FDA approval for their topical treatment of plaque psoriasis in adults. There are generic alternatives of calcipotriene and betamethasone available.

- **Belbuca™ (buprenorphine, buccal film)**: The FDA granted approval to Endo and Biodelivery Sciences for Belbuca. This is a buprenorphine buccal film to treat patients with chronic pain who need around-the-clock treatment and for whom current alternatives do not suffice.

- **Seebri™ Neohaler (glycopyrronium)**: Novartis received FDA approval for their twice-daily, long-acting muscarinic antagonist (LAMA) for the long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. Seebri will compete against Spiriva® and Tudorza™.

- **Utibron™ Neohaler (glycopyrronium and indacaterol)**: Novartis also received FDA approval for their LABA/LAMA combination for the long-term maintenance treatment of COPD. Utibron Neohaler will compete against Anoro® Ellipta and Stiolto™ Respimat.

New Generics

- **Surmontil® (trimipramine)**: The first generics of Teva’s Surmontil, a tricyclic antidepressant, have launched.

- **Viramune® XR (nevirapine ER)**: A generic version of Boehringer Inhelheim’s Viramune XR is now available. Viramune XR is used in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in children. According to IMS health, Viramune XR had approximately $67 thousand in annual U.S. sales.